China grants country's first Covid-19 vaccine patent to CanSino

CanSino said it is in talks with Russia, Brazil and Chile to launch Phase III trials in those countries. - Reuters

BEIJING, Aug 18 (Reuters): China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday (Aug 16).